# APG101 in Glioblastoma

> **NCT01071837** · PHASE2 · COMPLETED · sponsor: **Apogenix GmbH** · enrollment: 84 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** APG101
- **PROCEDURE:** Blood drawing

## Key facts

- **NCT ID:** NCT01071837
- **Lead sponsor:** Apogenix GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2015-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01071837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01071837, "APG101 in Glioblastoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01071837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*